Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population.
暂无分享,去创建一个
[1] J. Coste,et al. Human T-lymphotropic virus (HTLV) types I and II: seroprevalence among intravenous drug users in continental France. Retrovirus Study Group of the French Society of Blood Transfusion. , 1993, AIDS.
[2] M. Otto,et al. Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease which retains susceptibility to protease inhibitors. , 1995, Antiviral research.
[3] J. Albert,et al. Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates. , 1998, AIDS research and human retroviruses.
[4] A. Lapedes,et al. Timing the ancestor of the HIV-1 pandemic strains. , 2000, Science.
[5] B. Larder,et al. Mutations in Retroviral Genes Associated with Drug Resistance , 1996 .
[6] M. Nei,et al. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. , 1986, Molecular biology and evolution.
[7] J. Verhoef,et al. The prevalence of aminoglycoside resistance and corresponding resistance genes in clinical isolates of staphylococci from 19 European hospitals. , 1999, The Journal of antimicrobial chemotherapy.
[8] D. Gotte,et al. Virtually full-length subtype F and F/D recombinant HIV-1 from Africa and South America. , 2000, Virology.
[9] B. Korber,et al. Signature pattern analysis: a method for assessing viral sequence relatedness. , 1992, AIDS research and human retroviruses.
[10] Guy Burtonboy,et al. Variant Human Immunodeficiency Virus Type 1 Proteases and Response to Combination Therapy Including a Protease Inhibitor , 2001, Antimicrobial Agents and Chemotherapy.
[11] D. Swofford. PAUP*: Phylogenetic analysis using parsimony (*and other methods), Version 4.0b10 , 2002 .
[12] Martine Peeters,et al. Genetic Diversity of Protease and Reverse Transcriptase Sequences in Non-Subtype-B Human Immunodeficiency Virus Type 1 Strains: Evidence of Many Minor Drug Resistance Mutations in Treatment-Naive Patients , 2000, Journal of Clinical Microbiology.
[13] D. Katzenstein,et al. Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. , 1999, AIDS research and human retroviruses.
[14] J. Pillonel,et al. Increasing diversity of HIV‐1M serotypes in French blood donors over a 10‐year period (1985–1995) , 1997, AIDS.
[15] P. Sharp,et al. Genetic diversity of HIV-1: the moving target. , 2000, AIDS.
[16] S. Hammer,et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.
[17] M. Mouroux,et al. Polymorphism of the Human Immunodeficiency Virus Type 1 (HIV-1) Protease Gene and Response of HIV-1-Infected Patients to a Protease Inhibitor , 1999, Journal of Clinical Microbiology.
[18] D. Katzenstein,et al. Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe , 1997, Journal of virology.
[19] J. Goudsmit,et al. Circulation of subtype A and gagA/envB recombinant HIV type 1 strains among injecting drug users in St. Petersburg, Russia, correlates with geographical origin of infections. , 1999, AIDS research and human retroviruses.
[20] E. Wolf,et al. Large proportion of non-B HIV-1 subtypes and presence of zidovudine resistance mutations among German seroconvertors. , 1997, AIDS.
[21] Hideo Matsuda,et al. fastDNAmL: a tool for construction of phylogenetic trees of DNA sequences using maximum likelihood , 1994, Comput. Appl. Biosci..
[22] Z. Yang,et al. Approximate methods for estimating the pattern of nucleotide substitution and the variation of substitution rates among sites. , 1996, Molecular biology and evolution.
[23] D. Gotte,et al. Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants. , 1998, Virology.
[24] D J Hu,et al. Protease sequences from HIV-1 group M subtypes A–H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide , 2000, AIDS.
[25] David L. Robertson,et al. HIV-1 nomenclature proposal: a reference guide to HIV-1 classification. , 2000 .
[26] G. Learn,et al. HIV-1 Nomenclature Proposal , 2000, Science.
[27] K. Hertogs,et al. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting , 2001 .
[28] J. Baggs,et al. Impact of HIV type 1 subtype variation on viral RNA quantitation. , 1999, AIDS research and human retroviruses.
[29] R. Shafer,et al. Reproducibility of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase sequencing of plasma samples from heavily treated HIV-1-infected individuals. , 2000, Journal of virological methods.
[30] M. P. Cummings,et al. PAUP* Phylogenetic analysis using parsimony (*and other methods) Version 4 , 2000 .
[31] Bryan Chan,et al. Human immunodeficiency virus reverse transcriptase and protease sequence database , 2003, Nucleic Acids Res..
[32] John W. Mellors,et al. Human retroviruses and AIDS 1996. A compilation and analysis of nucleic acid and amino acid sequences , 1997 .
[33] F. Brun-Vézinet,et al. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. , 1998, AIDS.
[34] B. Korber,et al. Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease , 1997, Journal of virology.
[35] J. Fantini,et al. Use of drug resistance sequence data for the systematic detection of non-B human immunodeficiency virus type 1 (HIV-1) subtypes: how to create a sentinel site for monitoring the genetic diversity of HIV-1 at a country scale. , 2001, The Journal of infectious diseases.
[36] Soriano,et al. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance. , 2001, AIDS.
[37] D. Burke,et al. Identification of breakpoints in intergenotypic recombinants of HIV type 1 by bootscanning. , 1995, AIDS research and human retroviruses.
[38] D. Pieniążek,et al. Genetic Variation and Susceptibilities to Protease Inhibitors among Subtype B and F Isolates in Brazil , 1999, Antimicrobial Agents and Chemotherapy.
[39] P. Sharp,et al. A Comprehensive Panel of Near-Full-Length Clones and Reference Sequences for Non-Subtype B Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[40] T. Leitner,et al. Most HIV‐1 genetic subtypes have entered Sweden , 1997, AIDS.
[41] A. Jones-Trower,et al. Characterization and Enhanced Processing of Soluble, Oligomeric gp140 Envelope Glycoproteins Derived from Human Immunodeficiency Virus Type-1 Primary Isolates , 2001 .